Drug ID: 1d00000046
Drug Name: Alfacalcidol
Generic Names: Alpha D3 (1 mcg) | Alphadol (0.25 mcg) | Alfacip (1 mcg) | Alphadol (1 mcg) | Alfacal (0.5 mcg) | Alfacal | Minroset | Vitalpha (1 mcg) | Alfa D3 (0.25 mcg) | GR -Alpha | Alfacalcirol | Vitalpha | Zaxial | Alfabond | Qtr -Alfa | Alfa D3 (1 mcg) | One Alpha (1 mcg) | Alfabol Cap | Alfa Caps | Calfa D | Alfarich | One Alpha (0.25mcg) | Alfaset | Alpha D3 (0.5 mcg) | Alpha D3 | Alfacip | Calcit Sg | Alpha Calcirol | Alfa-D | One-Alpha
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: Adult- Oral- The recommended starting dose is 1mcg/day. Maintenance: 0.25-1 mcg/day.
Adult- IV- The recommended initial dose is 1 mcg per dialysis two to three times a week.
Recommended In: This medication is an analogue of vitamin D, prescribed for hypocalcaemia, hypoparathyroidism, hypophosphataemia, renal osteodystrophy, and osteomalacia. Since it does not require any activation process by kidneys like other vitamin D supplements, more useful for people who have kidney problems.
Directions For Use: It comes as a capsule to take by mouth, with food.
It also comes as a solution for injection to be administered by a healthcare provider into the vein.
Storage: Capsules: Store it at room temperature (25°C), and in an airtight container.
Injection: Store it in a cool place (below 15°C).
Dosage Forms: Capsule | Intravenous Injection
Side Effects: Gastrointestinal - Loss of appetite, nausea, vomiting, diarrhea and increased thirst.
Central Nervous System - Headache, fainting and lack of energy.
Skin - Increased sweating, itching, rash and hives.
Genitourinary: - Increased urination, kidney impairment, and excessive urinary calcium excretion.
In Case of Overdose: The effects of administered vitamin D can persist for two or more months after cessation of treatment.
Hypervitaminosis D is characterized by:
Hypercalcemia with anorexia, nausea, weakness, weight loss, vague aches and stiffness, constipation, mental retardation, anemia, and mild acidosis.
Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, or irreversible renal insufficiency which may result in death.
Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Bone demineralization (osteoporosis) in adults occurs concomitantly.
Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism).
The treatment of hypervitaminosis D with hypercalcemia consists in immediate withdrawal of the vitamin, a low calcium diet, generous intake of fluids, along with symptomatic and supportive treatment. Hypercalcemic crisis with dehydration, stupor, coma, and azotemia requires more vigorous treatment. The first step should be hydration of the patient. Intravenous saline may quickly and significantly increase urinary calcium excretion. A loop diuretic (furosemide or ethacrynic acid) may be given with the saline infusion to further increase renal calcium excretion. Other reported therapeutic measures include dialysis or the administration of citrates, sulfates, phosphates, corticosteroids, EDTA (ethylenediaminetetraacetic acid), and mithramycin via appropriate regimens. With appropriate therapy, recovery is the usual outcome when no permanent damage has occurred. Deaths via renal or cardiovascular failure have been reported.
Avoid If: Caution should be exercised in patients with history of kidney stones, heart or kidney disease, high level of calcium in blood, any allergy, who are taking other medications, during pregnancy and breastfeeding.
Monitor blood electrolytes level regularly while taking this medication.
Monitor serum levels of calcium in patients with kidney failure.
Contraindicated in patients with high blood calcium, phosphate, and magnesium and known hypersensitivity.
Drug Interaction: Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with Alfacalcidol may cause hypercalcemia.